Luca Guerra
YOU?
Author Swipe
View article: Advanced stage classical Hodgkin lymphoma patients with a positive interim-PET (PET-2) Deauville score 5 after 2 ABVD cycles: a pooled analysis of three multicenter trials
Advanced stage classical Hodgkin lymphoma patients with a positive interim-PET (PET-2) Deauville score 5 after 2 ABVD cycles: a pooled analysis of three multicenter trials Open
View article: Next-generation radiomic sequencing in non-small cell lung cancer: an alternative model to predict mutations from [18F]FDG PET/CT
Next-generation radiomic sequencing in non-small cell lung cancer: an alternative model to predict mutations from [18F]FDG PET/CT Open
Background: Non-small cell lung cancer (NSCLC) remains the most common cause of cancer-related mortality worldwide. The introduction of targeted therapies against oncogenic drivers, particularly EGFR and KRAS mutations, has significantly i…
View article: Characterizing amyloid and tau PET-based stages across the clinical continuum
Characterizing amyloid and tau PET-based stages across the clinical continuum Open
Staging the severity of Alzheimer’s disease pathology using biomarkers is central to early detection and therapeutic trial design. In this cross-sectional study, we standardized amyloid and tau PET data across multiple cohorts to character…
View article: Comparison of amyloid PET acquired through standardized and unstandardized protocols
Comparison of amyloid PET acquired through standardized and unstandardized protocols Open
INTRODUCTION Amyloid positron emission tomography (PET) scans collected by Alzheimer's Disease Research Centers (ADRCs) include site‐specific “mixed protocols” and, since 2021, standardized protocols through the Standardized, Centralized A…
View article: 223 | PROGNOSTIC ROLE OF INTERIM ΔSUVmax IN FOLLICULAR LYMPHOMA
223 | PROGNOSTIC ROLE OF INTERIM ΔSUVmax IN FOLLICULAR LYMPHOMA Open
View article: 411 | THE SEARCH FOR BASELINE IMAGING PREDICTIVE FACTORS OF REFRACTORINESS TO ABVD IN THE LOW AND VERY LOW RISK PATIENTS WITH EARLY STAGES HL OF THE RAFTING TRIAL
411 | THE SEARCH FOR BASELINE IMAGING PREDICTIVE FACTORS OF REFRACTORINESS TO ABVD IN THE LOW AND VERY LOW RISK PATIENTS WITH EARLY STAGES HL OF THE RAFTING TRIAL Open
View article: 417 | TMTV < THAN 32.5 mL IMPAIRS THE SUCCESSFUL DETECTION OF ctDNA IN EARLY‐STAGE HODGIN LYMPHOMA PATIENTS—THE PRELIMINARY REPORT FROM THE RAFTING TRIAL
417 | TMTV < THAN 32.5 mL IMPAIRS THE SUCCESSFUL DETECTION OF ctDNA IN EARLY‐STAGE HODGIN LYMPHOMA PATIENTS—THE PRELIMINARY REPORT FROM THE RAFTING TRIAL Open
View article: Total Metabolic Tumor Volume Is a Strong Independent Prognostic Factor in Follicular Lymphomas: Results From a Sub‐Study of the <scp>FOLL12</scp> Trial
Total Metabolic Tumor Volume Is a Strong Independent Prognostic Factor in Follicular Lymphomas: Results From a Sub‐Study of the <span>FOLL12</span> Trial Open
Discordant results have been generated regarding the prognostic role of Total Metabolic Tumor Volume (TMTV) in Follicular Lymphoma (FL). The use of prospective data and the adoption of the newly defined standardized SUV4 method for calcula…
View article: Otoprotective measures for cisplatin-induced toxicity in chemoradiotherapy for head and neck cancer patients: a systematic review
Otoprotective measures for cisplatin-induced toxicity in chemoradiotherapy for head and neck cancer patients: a systematic review Open
View article: Prognostic role of interim PET in follicular lymphoma: a post hoc study of FOLL12 trial by Fondazione Italiana Linfomi
Prognostic role of interim PET in follicular lymphoma: a post hoc study of FOLL12 trial by Fondazione Italiana Linfomi Open
We analyzed metabolic response using interim positron emission tomography scan (iPET) in a subset of patients with follicular lymphoma (FL) enrolled in the randomized FOLL12 trial. Patients with grade 1-3a FL with an iPET performed between…
View article: International Benchmark for Total Metabolic Tumor Volume Measurement in Baseline<sup>18</sup>F-FDG PET/CT of Lymphoma Patients: A Milestone Toward Clinical Implementation
International Benchmark for Total Metabolic Tumor Volume Measurement in Baseline<sup>18</sup>F-FDG PET/CT of Lymphoma Patients: A Milestone Toward Clinical Implementation Open
Total metabolic tumor volume (TMTV) is prognostic in lymphoma. However, cutoff values for risk stratification vary markedly, according to the tumor delineation method used. We aimed to create a standardized TMTV benchmark dataset allowing …
View article: Carbapenem-Resistant <i>Acinetobacter</i> spp Infection in Critically Ill Patients With Limited Treatment Options: A Descriptive Study of Cefiderocol Therapy During the COVID-19 Pandemic
Carbapenem-Resistant <i>Acinetobacter</i> spp Infection in Critically Ill Patients With Limited Treatment Options: A Descriptive Study of Cefiderocol Therapy During the COVID-19 Pandemic Open
Background Carbapenem-resistant Acinetobacter baumannii infections are difficult to treat and are a significant public health threat due to intrinsic/acquired resistance and limited treatment options. Methods A retrospective, observational…
View article: Prognostic value of the end of induction PET in patients with follicular lymphoma: results from the analysis of FOLL 12 trial
Prognostic value of the end of induction PET in patients with follicular lymphoma: results from the analysis of FOLL 12 trial Open
Aim: To assess the prognostic value of the PET metabolic response using the Deauville Score at the end of induction (EoI) therapy. Methods: FOLL12 trial (NCT02063685) is a multicenter, phase III, randomized study with the primary objective…
View article: COMBINED USE OF MINIMAL RESIDUAL DISEASE MONITORING AND FDG‐PET FOR OUTCOME PREDICTION IN FOLLICULAR LYMPHOMA: RESULTS FROM THE FONDAZIONE ITALIANA LINFOMI (FIL) FOLL12 TRIAL
COMBINED USE OF MINIMAL RESIDUAL DISEASE MONITORING AND FDG‐PET FOR OUTCOME PREDICTION IN FOLLICULAR LYMPHOMA: RESULTS FROM THE FONDAZIONE ITALIANA LINFOMI (FIL) FOLL12 TRIAL Open
Introduction: In follicular lymphoma (FL), FDG-PET is routinely employed to evaluate response at the end of induction (EoI), while minimal residual disease (MRD) analysis is highly reliable in predicting relapse over the entire disease his…
View article: Baseline‐PET derived metrics are the most relevant factors for risk stratification in early‐stage nonbulky HL: preliminary results of the RAFTING trial
Baseline‐PET derived metrics are the most relevant factors for risk stratification in early‐stage nonbulky HL: preliminary results of the RAFTING trial Open
Introduction: The efficacy of combined-modality treatment (Tx) with chemotherapy (CT) and radiotherapy (RT) in early-stage Hodgkin Lymphoma (eHL) is offset by long-term morbidity, with a cumulative incidence of 2nd primary malignancy at 40…
View article: The impact of spleen metabolic tumor volume on total metabolic tumor volume and prognosis in patients with follicular lymphoma enrolled in FOLL 12 trial
The impact of spleen metabolic tumor volume on total metabolic tumor volume and prognosis in patients with follicular lymphoma enrolled in FOLL 12 trial Open
Introduction and Aim: Recently, in an ancillary study of FOLL12 trial (NCT02063685), total Metabolic Tumor Volume (tMTV) assessed before treatment has been demonstrated to be an independent predictor of PFS in patients receiving frontline …
View article: 18F-FDG PET/CT Maximum Tumor Dissemination (Dmax) in Lymphoma: A New Prognostic Factor?
18F-FDG PET/CT Maximum Tumor Dissemination (Dmax) in Lymphoma: A New Prognostic Factor? Open
Recently, several studies introduced the potential prognostic usefulness of maximum tumor dissemination (Dmax) measured by 2-deoxy-2-fluorine-18-fluoro-D-glucose positron-emission tomography/computed tomography (18F-FDG PET/CT). Dmax is a …
View article: Predictive value on advance hodgkin lymphoma treatment outcome of end‐of treatment FDG PET/CT in the HD0607 clinical trial
Predictive value on advance hodgkin lymphoma treatment outcome of end‐of treatment FDG PET/CT in the HD0607 clinical trial Open
The Lugano classification for response assessment in lymphoma recommends the use of the 5‐point‐scale Deauville Score (DS) to assess response evaluation of end‐of‐treatment FDG‐PET/CT (eotPET) in Hodgkin Lymphoma (HL); nevertheless, there …
View article: T021: Radiation-Free Therapy as the INitial treatment of Good-prognosis early non-bulky Hodgkin lymphoma, defined by a low Metabolic Tumor Volume and a negative PET-2 - RAFTING Trial.
T021: Radiation-Free Therapy as the INitial treatment of Good-prognosis early non-bulky Hodgkin lymphoma, defined by a low Metabolic Tumor Volume and a negative PET-2 - RAFTING Trial. Open
Figure 1: RAFTING Trial workflow Introduction: The efficacy of combined modality treatment (CMT) with chemotherapy (CT) and radiotherapy (RT) in early-stage Hodgkin Lymphoma (eHL) is offset by long-term morbidity, with a cumulative inciden…
View article: P004: Advanced stage classical Hodgkin lymphoma (cHL) patients with a positive interim-PET (PET-2) Deauville score (DS) 5 after 2 ABVD cycles: A pooled analysis of individual patient data of three multicenter trials
P004: Advanced stage classical Hodgkin lymphoma (cHL) patients with a positive interim-PET (PET-2) Deauville score (DS) 5 after 2 ABVD cycles: A pooled analysis of individual patient data of three multicenter trials Open
Background: PET-2 is widely adopted to select patients (pt) with advanced-stage cHL, who might benefit from intensifying or de-escalating therapy. Improved PFS has been reported in PET-2 positive pt switched from ABVD to escalated BEACOPP …
View article: Validity of cingulate–precuneus–temporo-parietal hypometabolism for single-subject diagnosis of biomarker-proven atypical variants of Alzheimer’s Disease
Validity of cingulate–precuneus–temporo-parietal hypometabolism for single-subject diagnosis of biomarker-proven atypical variants of Alzheimer’s Disease Open
The aim of our study was to establish empirically to what extent reduced glucose uptake in the precuneus, posterior cingulate and/or temporo-parietal cortex (PCTP), which is thought to indicate brain amyloidosis in patients with dementia o…
View article: Response-Adapted Postinduction Strategy in Patients With Advanced-Stage Follicular Lymphoma: The FOLL12 Study
Response-Adapted Postinduction Strategy in Patients With Advanced-Stage Follicular Lymphoma: The FOLL12 Study Open
PURPOSE We compared 2 years of rituximab maintenance (RM) with a response-adapted postinduction approach in patients with follicular lymphoma who responded to induction immunochemotherapy. METHODS We randomly assigned treatment-naïve, adva…
View article: Cardiotoxicity in breast cancer patients: the role of gated myocardial perfusion SPECT
Cardiotoxicity in breast cancer patients: the role of gated myocardial perfusion SPECT Open
Funding Acknowledgements Type of funding sources: None. Background Patients undergoing chemotherapy (CHT) for breast cancer (BC) need a monitoring of cardiac function due to the possible onset of cardiotoxicity. Cardiotoxicity may occur wi…
View article: EARLY METABOLIC RESPONSE IN FOLLICULAR LYMPHOMA: A SUBSET ANALYSIS OF THE FOLL12 TRIAL BY THE FONDAZIONE ITALIANA LINFOMI (FIL)
EARLY METABOLIC RESPONSE IN FOLLICULAR LYMPHOMA: A SUBSET ANALYSIS OF THE FOLL12 TRIAL BY THE FONDAZIONE ITALIANA LINFOMI (FIL) Open
Background: A small but significant proportion of patients with Follicular Lymphoma (FL) shows an aggressive behavior. Among available prognostic tools the duration of response and metabolic response (MR) after completion of immunochemothe…
View article: The heterogeneity of lung perfusion patterns in SPECT/CT during COVID-19: not only embolism
The heterogeneity of lung perfusion patterns in SPECT/CT during COVID-19: not only embolism Open
View article: Metabolic Parameters as Biomarkers of Response to Immunotherapy and Prognosis in Non-Small Cell Lung Cancer (NSCLC): A Real World Experience
Metabolic Parameters as Biomarkers of Response to Immunotherapy and Prognosis in Non-Small Cell Lung Cancer (NSCLC): A Real World Experience Open
Immune-checkpoint inhibitors (ICIs) have been proven to have great efficacy in non-small cell lung cancer (NSCLC) as single agents or in combination therapy, being capable to induce deep and durable remission. However, severe adverse event…
View article: Recent Advances in the Evaluation of Serological Assays for the Diagnosis of SARS-CoV-2 Infection and COVID-19
Recent Advances in the Evaluation of Serological Assays for the Diagnosis of SARS-CoV-2 Infection and COVID-19 Open
Introduction: Few data on the diagnostic performance of serological tests for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection are currently available. We evaluated sensitivity and specificity of five different widely…
View article: Prevalence of interstitial pneumonia suggestive of COVID-19 at 18F-FDG PET/CT in oncological asymptomatic patients in a high prevalence country during pandemic period: a national multi-centric retrospective study
Prevalence of interstitial pneumonia suggestive of COVID-19 at 18F-FDG PET/CT in oncological asymptomatic patients in a high prevalence country during pandemic period: a national multi-centric retrospective study Open
View article: Radiolabeled fibroblast activation protein inhibitor (FAPI) PET in oncology: has the time come for 18F-fluorodeoxyglucose to think to a well-deserved retirement?
Radiolabeled fibroblast activation protein inhibitor (FAPI) PET in oncology: has the time come for 18F-fluorodeoxyglucose to think to a well-deserved retirement? Open
View article: Consolidation Radiotherapy Could Be Safely Omitted in Advanced Hodgkin Lymphoma With Large Nodal Mass in Complete Metabolic Response After ABVD: Final Analysis of the Randomized GITIL/FIL HD0607 Trial
Consolidation Radiotherapy Could Be Safely Omitted in Advanced Hodgkin Lymphoma With Large Nodal Mass in Complete Metabolic Response After ABVD: Final Analysis of the Randomized GITIL/FIL HD0607 Trial Open
PURPOSE To investigate the role of consolidation radiotherapy (cRT) in advanced-stage Hodgkin lymphoma (HL) presenting at baseline with a large nodal mass (LNM) in complete metabolic response after doxorubicin, bleomycin, vinblastine, and …